Articles tagged with Hiv Infections
Researchers identified a new link in the chain allowing HIV to overcome cellular resistant factor and infect human cells. Disruption of Cul5-SCF function reduces HIV infectiousness by 90%, paving the way for new therapies.
The study found substantial survival increases after HAART, with death rates reduced by 50% in 1997 and over 80% by 2001. Injecting drug users had four times higher death rates than those infected through homosexual contact. Earlier diagnosis maximizes treatment gains.
Rao's research aims to understand the mechanism of virus assembly, a crucial step in viral transmission and disease spread. By studying the brome mosaic virus, his lab hopes to develop new strategies for blocking virus assembly and preventing disease.
A study found that PET scans can detect activation of lymph nodes in HIV-infected individuals, suggesting potential targets for treatment. Researchers propose using PET scans to locate active nodes and target them with radiation or removal.
Researchers found distinct lymphoid tissue activation patterns in patients with acute, mid-stage, and late HIV-1 disease. PET scans showed predictable sequence of lymph node involvement, suggesting potential for treatment interruptions during active node removal.
A randomized clinical trial will test whether daily tenofovir prevents HIV infection in 800 high-risk, uninfected Cambodian women. The study aims to evaluate the effectiveness of the antiviral drug for preventing HIV-1 transmission in people.
An interim analysis of a study comparing TDF to EFV in combination with 3TC + ABC found that the TDF arm had a higher rate of virologic non-response. The study included 194 patients and showed that VL <400 copies/mL was achieved in 49% of TDF subjects, compared to 90% of EFV subjects.
Researchers at Columbia University discovered that D-beta-hydroxybutyrate restores impaired brain function and protects against neurodegeneration in mice with Parkinson's disease. The study supports a critical role for mitochondrial defects in the progression of the disease.
A study suggests that new HIV treatments can lead to a decrease in people's concerns about the disease, resulting in increased transmission rates. Researchers believe that health professionals should address this issue by revamping prevention messages and programs.
The study found that the three-drug combination of abacavir, lamivudine, and efavirenz provided a potent antiretroviral response over 48 weeks. Subjects in the ABC/3TC/EFV group had a significantly better immunologic response compared to those in the ZDV/3TC/EFV group.
A study challenges previous views on HIV-infected T cell lifespan, revealing that chronic immune activation drives high proliferation rates in memory T cells. HAART treatment improves long-lived T cell production, providing insight into the body's response to HIV infection.
A study published in The Lancet found that people with HIV who are successfully treated with HAART and hepatitis C negative have a mortality rate similar to those with cancer. This preliminary actuarial evidence supports the idea that life coverage could be considered under specific conditions.
A recent study published in Johns Hopkins Medicine found that giving one dose of nevirapine to HIV-positive mothers during labor and their newborns reduced transmission by 41 percent. The simple regimen has the potential to prevent hundreds of thousands of new infections every year.
A long-term study found that nevirapine sustained a 41% reduction in HIV infection risk compared to azidothymidine (AZT) in infants born to breastfeeding mothers. The regimen showed significant cost savings, approximately 70 times less than AZT treatment.
Researchers found that total lymphocyte count and hemoglobin concentration decline rapidly in individuals who develop AIDS, with over 77% of study participants exhibiting these declines. This finding offers an alternative to current HIV diagnosis methods, which require expensive technology and equipment.
A genetically engineered strain of lactobacillus could significantly inhibit HIV infection in humans, offering a safe and long-lasting way to protect women. The research uses naturally colonizing bacteria to block and inactivate viruses before they reach host cells.
Researchers suggest that heightening immune response against human proteins in viral envelope could prevent HIV infection, offering a potential solution for reducing transmission rates. This approach, called alloimmunization, has the advantage of working against all strains of HIV and other retroviruses.
Purdue University chemist Jean Chmielewski has won a national award for developing new compounds that disrupt the AIDS virus's ability to reproduce. Her approach involves creating molecular 'wedges' that block HIV proteins from binding together, promising initial results in testing with infected cells.
The UNC-led trial is the first human test of an HIV vaccine pioneered at UNC. The vaccine targets cells in lymph nodes and induces an immune response by expressing a small section of genetic material from HIV, aiming to protect against disease if exposed. Researchers hope to refine the vaccine for subsequent generations.
A recent University of Pittsburgh study found that women with bacterial vaginosis (BV) are nearly twice as likely to get herpes simplex virus type 2 (HSV-2). The study, which involved over 1,200 sexually active women, suggests that more comprehensive screening and treatment could reduce susceptibility to HSV-2.
Researchers found that rare variations of HLA-A and HLA-B genes can protect against HIV. The study, which analyzed data from 996 HIV-infected men in Chicago, suggests that these genetic variants may be used to develop targeted AIDS vaccines.
A research team led by Nathaniel Landau identified the interaction between HIV's Vif protein and APOBEC3G. The study found that mice have a similar antiviral protein that can block HIV replication due to its inability to recognize human proteins.
A new study published in Nature Medicine has found that certain human genes can predict the progression rate of AIDS in infected individuals. The researchers analyzed data from a large group of homosexual men with HIV and found that those with specific HLA protein types were more likely to succumb to the disease quickly.
A recent study in Beijing found that men who have sex with men (MSM) are at risk of HIV-1 infection, with 15 out of 481 participants testing positive. The study highlights the potential for MSM to serve as a bridge between high-risk and low-risk populations, increasing the transmission of HIV-1.
Researchers analyzed lipid levels of HIV patients before and during HAART and found that average total and LDL cholesterol levels remained stable over three years. After initiation, cholesterol levels rose but returned to pre-infection levels after a year. However, triglyceride and HDL levels were higher than in similar-aged men.
Failure to meet HIV prevention goals may result in significant financial losses. The CDC's national goal of reducing new infections by 50% might not be met by 2005, leading to an estimated $18 billion in incurred net medical costs between now and 2010.
A study by Margaret A. Chesney found that noninjection drug use and unprotected receptive anal sex were the most likely predictors of risky sexual behavior among gay men, accounting for only one-third of cases. One-on-one counseling tailored to individual behaviors may be effective in preventing new HIV infections.
The STAT program uses a combination of antibody tests and polymerase chain reaction (PCR) to detect acute HIV infections, which are often missed by routine testing. The approach has resulted in a 4% increase in new HIV diagnoses in North Carolina and has shown promise for reducing transmission and saving lives.
Researchers found nearly a third of HIV positive male couples became parents through assisted reproduction, while only one out of ten HIV positive female couples were successful. The study's findings suggest HIV positive men may be more suitable candidates for fertility treatments due to lower infection rates.
A study of 487 cocaine-dependent patients found that treatment combining group drug counseling with individual therapy reduced HIV risk. The combination treatment showed the best improvements in reducing cocaine use, resulting in a 40% decrease in HIV risk.
A new vaccine has shown promise in inducing an HIV-specific immune response in patients with chronic HIV infection, but further research is needed to evaluate its clinical effect. The vaccine, Remune, was found to increase the production of T helper cells that recognize and attack the virus.
A national survey found significant support for HIV vaccine research, with 84% of the public believing efforts to develop a vaccine are 'extremely' or 'very' important. However, there is also concern about misconceptions about vaccine development and testing. The survey highlighted the need for education on ongoing HIV vaccine research.
Researchers identify a helpful gene mutation in the Vpr gene of long-term nonprogressive HIV patients, which impairs the HIV virus' cell-killing machinery. The presence or absence of this mutation may play a central role in determining which patients develop fatal AIDS.
A study by Mayo Clinic researchers found that a specific Vpr mutation is associated with long-term nonprogressive HIV infection, where infected individuals exhibit preserved immune function. The discovery suggests a potential therapeutic opportunity for Vpr inhibitors to reduce T cell death during HIV infection.
HIV-infected individuals with a history of alcohol problems who consume moderate or at-risk amounts of alcohol have higher viral loads and lower CD4 cell counts compared to non-drinkers. Heavy alcohol consumption is linked to increased disease progression, nonadherence to treatment, and worsened comorbid conditions.
Researchers at Columbia University have made significant discoveries in understanding the immune system and brain function, including the identification of key genes involved in odor recognition. Their work has provided new insight into how smell is represented in the brain.
Researchers documented how HIV enters human T cells, where it multiplies and subverts the immune system, using time-lapse microscopy. The study reveals that HIV exploits the dendritic cell's special relationship with T cells to gain entry and launch its assault.
The editorial emphasizes that providing affordable drugs is insufficient to combat HIV in the developing world. Comprehensive medical care, including training for healthcare workers and laboratory tests, must also be included to make Highly Active Antiretroviral Therapy (HAART) effective.
A study found that counseling interventions reduced unprotected sex acts among HIV-positive participants by an average of 10 from 14 to 4 per year. However, a group receiving booster sessions showed an unexpected upswing in unprotected sex eight months after intervention, suggesting the need for longer-term follow-up.
A new predictive system identifies two DNA polymorphisms that distinguish between HBV-positive patients who respond well to lamivudine treatment and those who develop resistance. The study's findings have significant implications for the treatment of chronic hepatitis B, potentially saving millions from liver disease and cancer.
The American College of Preventive Medicine recommends widespread screening for chlamydia in high-risk populations due to its high prevalence and asymptomatic cases. Effective screening can lead to timely diagnosis and treatment, reducing the risk of pelvic inflammatory disease and other long-term complications.
A study published in the Journal of Infectious Diseases found that people undergoing hemodialysis are 257 times more likely to contract Staphylococcus aureus (ISA) than the general population. Those with HIV, solid organ transplant recipients, and heart disease patients are also at increased risk.
Researchers at Achillion Pharmaceuticals and the University of Maryland, Baltimore (UMBC) have identified a new class of compounds that inhibit a novel target in HIV. These compounds disrupt the assembly of the HIV-1 capsid protein, which is essential for viral maturation.
A study by Johns Hopkins Bloomberg School of Public Health reveals that Pakistani and Afghan drug users are at high risk of HIV due to limited knowledge and risky behaviors. The research highlights the need for interventions such as needle exchange programs and drug treatments to prevent blood-borne infections.
Researchers found that HIV patients develop strong antibody responses against the virus, but these antibodies fail to keep pace with the virus's constant mutation process. This study sheds light on the complex dynamics between the immune system and HIV, highlighting potential avenues for vaccine development.
Researchers studied sooty mangabey monkeys infected with SIV, finding they didn't get sick like humans with HIV. The lack of symptoms was attributed to low-level immune system responses and ability to maintain T cell renewal.
A study in Alberta found that mandatory reporting of HIV infection did not significantly impact testing rates among the general population. However, an opt-out prenatal screening policy resulted in a dramatic increase in female tests, suggesting that fear of receiving a positive test may be a more significant deterrent to testing.
Researchers found that alcohol consumption increased host susceptibility to SIV/HIV infection by increasing infectivity of cells and lymphocyte turnover. The study suggests that chronic or binge alcohol consumption may contribute to the risk of HIV infection, particularly through behavioral factors.
Researchers discover protein from blue-green algae that inhibits both HIV and Ebola virus infections, potentially leading to new treatments. The protein works by binding to the outside of the viruses and blocking them from entering cells.
A recent study found that 95% of skin penetration operators believe guidelines are needed, but only half follow them. Tattoo shop operators were more knowledgeable about infection control than others. Barriers to compliance include client perceptions and busy schedules.
A 12-week study in Baltimore evaluated nevirapine for HIV prevention in adults at high risk, showing no serious side effects or new infections. The researchers discovered that the three lower doses of nevirapine provided sufficient blood levels to potentially prevent HIV infection.
The study found increased condom use in intervention groups but no impact on HIV incidence, highlighting the need for more effective STI and behavioral interventions to control HIV in Uganda. The researchers emphasize the importance of rigorous evaluation and development of promising interventions.
Scientists at Imperial College London have discovered a unique method of viral transmission by the HTLV-1 leukaemia virus. The virus infects cells and transfers itself to other cells without releasing particles, evading the immune system and paving the way for potential new treatments.
The US has pledged $1 billion to combat HIV/AIDS in 14 high-prevalence countries. The programme aims to prevent 7 million new infections, treat 2 million people, and support 10 million infected individuals.
A recent study found that 78% of HIV-positive N.C. men and women prisoners had unprotected sex with their main partner in the year before imprisonment. Upon release, 26% admitted to having sex without condoms with that same person within a day or two.
A new vaccine based on a chimpanzee adenovirus has shown promise against HIV by inducing a powerful T-cell-based immune response in mice. The vaccine avoids the issue of pre-existing immunity seen with human adenovirus vaccines.
China's blood banking system is fragmenting due to rural-urban differences and has a scarcity of volunteer donors, leading to paid donations and illegal activities. Improvements are needed to adopt a volunteer-donor-only system, increasing education and training for those involved in blood collection and transfusion.
The NIH has awarded nearly $8 million to the University of Pittsburgh and Magee-Womens Research Institute to develop a microbicide barrier to prevent HIV transmission in women. The project aims to create a safe and effective way for women to protect themselves against sexually transmitted infections, including HIV.
Researchers have successfully created a delivery system using a vehicle derived from HIV itself to introduce synthetic siRNAs into human cells. This approach aims to prevent HIV infection by knocking out the CCR5 receptor, which is found on T-cells and plays a role in immune function.
A study by Johns Hopkins Medicine found that HIV increases the severity of hepatitis B infections, leading to higher liver disease-related deaths among men with both conditions. The research suggests physicians may see an increase in hepatitis B-related liver disease among the 1 million people living with HIV in the US.